Results 1 - 10 of 55 : 1 2 3 4 5 6 Next
The drugmaker gets its licenses to distribute controlled substances reinstated.
Bristol-Myers Puts Icahn and ImClone to the Test
Bristol and Icahn both go hostile toward each other.
King's Unstoppable Urge to Merge
Your potential acquisition isn't interested? Go for the hostile takeover!
The pharmaceutical makes an all-in bet on an unproven market.
A Potentially Painless PDUFA Date
King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA.
It found a way to sell stuff it used to throw away.
It's hard to argue with across-the-board success.
5 Health Care Companies Flying Below the Radar
They've all got a potentially winning story.
More Group Therapy From Generics
The Teva deal for Barr shows consolidation is still underway in the industry.
If Johnson & Johnson sells its wound-care business, its partner could lose big.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK